These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 35042020)

  • 21. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study.
    da Silva NL; Takemoto MLS; Damasceno A; Fragoso YD; Finkelsztejn A; Becker J; Gonçalves MVM; Tilbery C; de Oliveira EML; Callegaro D; Boulos FC
    BMC Health Serv Res; 2016 Mar; 16():102. PubMed ID: 27009599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic Burden of Colorectal Cancer: A Case of Fars, Iran.
    Jafari A; Alamdarloo PM; Dehghani M; Bastani P; Ravangard R
    Cancer Control; 2021; 28():10732748211009952. PubMed ID: 33882706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Costs of multiple sclerosis in Panama from societal, patient perspectives and health-related quality of life.
    Gracia F; Larreategui M; Rodríguez G; Benzadón A; Ortiz M; Morales D; Domínguez C; Carrillo RE; Valderrama C; Lizán L; Armién B
    PLoS One; 2018; 13(10):e0204681. PubMed ID: 30304006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review.
    Pike J; Grosse SD
    Appl Health Econ Health Policy; 2018 Dec; 16(6):765-778. PubMed ID: 30094591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valuing productivity costs in a changing macroeconomic environment: the estimation of colorectal cancer productivity costs using the friction cost approach.
    Hanly P; Koopmanschap M; Sharp L
    Eur J Health Econ; 2016 Jun; 17(5):553-61. PubMed ID: 26022915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic burden of multiple sclerosis: a cross-sectional study in Iran.
    Rezaee M; Keshavarz K; Izadi S; Jafari A; Ravangard R
    Health Econ Rev; 2022 Jan; 12(1):2. PubMed ID: 34981265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression.
    Brown LJ; Li J; Brunner M; Snoke M; La HA
    J Med Econ; 2021; 24(1):140-149. PubMed ID: 33461357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjusted productivity costs of stroke by human capital and friction cost methods: a Northern Finland Birth Cohort 1966 study.
    Rissanen I; Ala-Mursula L; Nerg I; Korhonen M
    Eur J Health Econ; 2021 Jun; 22(4):531-545. PubMed ID: 33625624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ENCOMS: Argentinian survey in cost of illness and unmet needs in multiple sclerosis.
    Ysrraelit C; Caceres F; Villa A; Marcilla MP; Blanche J; Burgos M; Parera IC; Colombo O; Crespo E; Deri N; Labal P; Maluendez M; Martinez A; Melcon M; Nofal P; Reich E; Sinay V; Tarulla A; Vetere S; Barboza A; Rey R; Moreno M; Bacile A; Rojas JI; Kuperman G; Resk M; Seifer G; Machinicki G; Cuneo J
    Arq Neuropsiquiatr; 2014 May; 72(5):337-43. PubMed ID: 24863508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic costs incurred by the patients with multiple sclerosis at different levels of the disease: a cross-sectional study in Northwest Iran.
    Imani A; Gharibi F; Khezri A; Joudyian N; Dalal K
    BMC Neurol; 2020 May; 20(1):205. PubMed ID: 32446303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Societal costs of multiple sclerosis in Ireland.
    Carney P; O'Boyle D; Larkin A; McGuigan C; O'Rourke K
    J Med Econ; 2018 May; 21(5):425-437. PubMed ID: 29320900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating productivity costs using the friction cost approach in practice: a systematic review.
    Kigozi J; Jowett S; Lewis M; Barton P; Coast J
    Eur J Health Econ; 2016 Jan; 17(1):31-44. PubMed ID: 25387561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extent, consequences and economic burden of road traffic crashes in Iran.
    Rezaei S; Arab M; Karami Matin B; Akbari Sari A
    J Inj Violence Res; 2014 Jul; 6(2):57-63. PubMed ID: 24045158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cost burden of multiple sclerosis in the United States: a systematic review of the literature.
    Adelman G; Rane SG; Villa KF
    J Med Econ; 2013; 16(5):639-47. PubMed ID: 23425293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The costs of a multiple sclerosis relapse in Catalonia (Spain)].
    Casado V; Martinez-Yelamos S; Martinez-Yelamos A; Carmona O; Alonso L; Romero L; Moral E; Arbizu T
    Neurologia; 2006 Sep; 21(7):341-7. PubMed ID: 16977554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The increasing economic burden of multiple sclerosis by disability severity in Australia in 2017: Results from updated and detailed data on types of costs.
    Ahmad H; Campbell JA; van der Mei I; Taylor BV; Zhao T; Palmer AJ
    Mult Scler Relat Disord; 2020 Sep; 44():102247. PubMed ID: 32554286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity.
    Verstappen SM; Boonen A; Verkleij H; Bijlsma JW; Buskens E; Jacobs JW;
    Ann Rheum Dis; 2005 Dec; 64(12):1754-60. PubMed ID: 15860510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic consequences of multiple sclerosis for Canadians.
    Asche CV; Ho E; Chan B; Coyte PC
    Acta Neurol Scand; 1997 May; 95(5):268-74. PubMed ID: 9188900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Costs and quality of life of multiple sclerosis in Austria.
    Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
    Prescott JD; Factor S; Pill M; Levi GW
    J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.